Nivolumab and ipilimumab in recurrent or refractory cancer of unknown primary: a phase II trial
Maria Pouyiourou(German Cancer Research Center), Alwin Krämer(Heidelberg University), Tilmann Bochtler(Heidelberg University), Boris Kubuschok(University of Augsburg), Martina Kirchner(Heidelberg University), Albrecht Stenzinger(Heidelberg University), Markus Ball(Heidelberg University), Thomas Ernst(Jena University Hospital), Bianca Kraft(German Cancer Research Center), Michael Bitzer(University Children's Hospital Tübingen), Stefan Delorme(German Cancer Research Center), Daniel Kazdal(Heidelberg University), Ulrich Hacker(Leipzig University), Klaus Kluck(Heidelberg University), Timothy Wohlfromm(German Cancer Research Center), Thomas Hielscher(Ontario Institute for Cancer Research), H. Löffler(University of Mannheim), G Hübner, Philipp Schütt(Praxis für Hämatologie und Onkologie), Michael Ståhl(Berlin Institute of Health at Charité - Universitätsmedizin Berlin), Lena Weiss(LMU Klinikum)
Cited by 36
Related Papers
Medulloblastoma Comprises Four Distinct Molecular Variants
|Journal of Clinical Oncology|2010|1.4k
Cancer therapy shapes the fitness landscape of clonal hematopoiesis
|Nature Genetics|2020|739
Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial
|The Lancet Oncology|2019|486
New insights into the Tyrolean Iceman's origin and phenotype as inferred by whole-genome sequencing
|Nature Communications|2012|464